In 2020, the U.S. Food and Drug Administration (FDA) approved the FGFR kinase inhibitor,pemigatinib, as a second-line treatment for advanced CCA patients with FGFR2 fusions/rearrangements based on a single-arm phase II trial (FIGHT-202) [4, 5], followed by the approval of infigratinib in 2021 and futibatinib in 2022 [6, 7]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.